*Investigational New Drug authorization by FDA is done only after intense scrutiny and testing to prove Safety and effectiveness.
Adia Labs products are distributed for analytical testing and/or research use purposes and/or use with an FDA approved Investigational New Drug (IND) application, or other Institutional Review Board (IRB) approved protocols or similar. The use with patients should include full disclosure and a signed consent form
Allogenic Umbilical Cord Blood Plasma combined with Mononuclear Cells refers to a type of therapeutic approach or treatment that uses components derived from umbilical cord blood for medical purposes, often in the context of regenerative medicine, immunotherapy, or cell-based therapies.
This term means that the cells or tissue are derived from a donor (not the patient receiving the treatment). In this case, it refers to the use of umbilical cord blood collected from a donor, not the patient’s own blood.
The umbilical cord is rich in stem cells, plasma, and other regenerative factors. Plasma is the liquid component of blood, and it contains nutrients, hormones, and waste products. Cord blood plasma refers to the plasma portion of the blood extracted from the umbilical cord at birth.
These are cells that have a single nucleus (compared to other cells with multiple nuclei). In the context of cord blood, these cells usually include hematopoietic stem cells (which can develop into different types of blood cells), mesenchymal stem cells (which have regenerative properties), and various other immune cells. These cells are important because they can support tissue regeneration, repair, and immune modulation.
Thank you for your interest in our work at ADIA Med. We are committed to advancing MS research and improving patient outcomes. If you have any questions, need more information about our studies, or are interested in investing, our team is here to assist you. Please reach out using the contact form or through the provided contact details, and we will respond as quickly as possible. We look forward to connecting with you and exploring how we can work together to make a meaningful impact in the field of healthcare.